Since the compounds like C1 analog control TFEB activity independently of mTORC1 (mechanistic target of rapamycin (serine/threonine kinase) which is known to regulate multiple cellular processes; therefore these C1 analogs could play an important role in the treatment of neurodegenerative diseases (Martina et al., 2012). Here, MTOR is linked to neurodegenerative disease.